Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution

Published on March 30, 2026 at 7:05 am by Ramish Cheema in News

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Viking Therapeutics Inc. (NASDAQ:VKTX) is a biotechnology company developing treatments that focus on metabolic ailments. The firm is currently developing a weight loss drug under the title VK-2735 that is designed to work on GLP-1 and GIP receptors. Viking Therapeutics Inc. (NASDAQ:VKTX)’s shares are up by 34% over the past year and are slightly down since Cramer discussed the firm in January 28 on Mad Money. One major reason behind the lackluster performance is a massive drop in August 2025 when Viking Therapeutics Inc. (NASDAQ:VKTX)’s stock closed 42% lower on the 19th. On that day, the firm released results of its mid-stage trial of the drug. The trial saw participants lose 12% of their body weight, while, according to media reports, investors were aiming for higher percentages. Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK-2735 is a weight loss pill, and in late 2025, Novo Nordisk became the first to launch such a product. The performance also vindicated Cramer, as he had remarked:

“Okay, people, people think that even if Lily’s stock can’t go up, why would we want Viking Therapeutics? And a lot of people were in it for a takeover. So far it doesn’t look like that’s materializing, so they’re giving up and they are selling it. I prefer Eli Lilly.”